Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of 0.02% atropine sulfate eye drops for controlling myopia progression in children
CTR20233851Phase 3Active
- Sponsor
- Zhejiang Shapuaisi Pharmaceutical
- Start
- Dec 2023
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atropine in myopia, sponsored by Zhejiang Shapuaisi Pharmaceutical. Started Dec 2023; status: active.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on CTR20233851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233851.